An observational study in Cardiac Failure and Respiratory Failure, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by University Hospital, Strasbourg, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 448 studies in Heart Failure with a site in France — 90 open to participants now, 116 under way, 16 of them phase 3. Heart Failure · France.
Among the 448 studies in Heart Failure with a site in France, this one is the 137th largest by planned enrollment of the 161 observational ones that give a count, is one of 29 that started in 2025, is one of 161 observational ones, reaches primary completion later than 43 of the 115 other live ones, and was the 418th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →90 of the 448 studies in Heart Failure with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18–90
University Hospital, Montpellier · Sites in France
Ages 18+
Oslo University Hospital · Sites in France, United States, Belgium and 7 more countries
Ages 18+
AstraZeneca · Sites in France, United States, Argentina and 29 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
448 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 28 · Phase 3 70 · Phase 4 15
First in 1983; this study’s year is marked. 29 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 196 across the 282 interventional studies, 321 across the 161 observational. Of the 290 that completed or were terminated, 74 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 448 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
University Hospital, Strasbourg, France has 9 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
28 of the studies in Heart Failure with a site in France that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020263Phase 3Pr Bruno LEVYEffect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock | 2027-02-03 |
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06518694Phase 3Assistance Publique - Hôpitaux de ParisBeta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction | 2027-10 |
Add all 28 to your calendar (.ics) → With an account.
Among the 448 studies in Heart Failure with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Advances in flow cytometry techniques have led to a better understanding of platelet phenotypes and have revealed the existence of four major platelet populations with distinct functional properties (native, proaggregating, procoagulating, or apoptotic). These phenotypes have a significant impact on the hemostatic capacity of blood platelets, and a proportional change in these populations during ECMO treatment could, at least in part, contribute to the observed complications.
- Adult patient (≥18 years) treated in one of the intensive care units of the Anesthesia and Intensive Care Department at Strasbourg University Hospital and implanted with veno-arterial or veno-venous ECMO within the previous 24 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic)
Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic) on Days 1, 3, and 7 after the initiation of ECMO treatment.
Time frame: Days 1, 3, and 7 after the initiation of ECMO treatment.
Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →